Enliven Therapeutics, Inc. (ELVN) company profile
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
About Enliven Therapeutics
Pharmaceutical Preparations, SIC 2834
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies. The company applies a precision medicine approach rooted in validated biological targets and differentiated chemistry to improve survival outcomes and quality of life for patients. Its primary clinical program centers on ELVN-001, a potent and selective ATP-competitive tyrosine kinase inhibitor targeting the BCR-ABL gene fusion for individuals with chronic myeloid leukemia. In addition to its core oncology program, Enliven engages in research-stage opportunities across other medical areas, including discovery efforts directed toward Graves' disease.
The company operates primarily at a clinical and discovery development stage, conducting clinical trials including the ENABLE Phase 1 study and planned Phase 3 evaluations. It holds global commercial rights to its internal pipeline assets while exploring strategic collaborations and options for programs such as ELVN-002. Enliven's primary operations and corporate headquarters are located in Boulder, Colorado.
Summary of the business section of Enliven Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Enliven Therapeutics, Inc.
- Headquarters
- Burlingame, CA
- Address
- 205 Park Road 94010
- Phone
- (650) 547-5814
- Website
- enliventherapeutics.com
- Employees
- 60, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- ELVN
- Former tickers
- IMRA until Mar 1, 2023
- Exchange
- Nasdaq
- IPO date
- Mar 12, 2020
- Shares outstanding
- 73M, Jul 28, 2026
- Public float
- $836.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-8.33 reverse, May 11, 2023
- SEC CIK
- 1672619
- CUSIP
- 29337E102
- ISIN
- US29337E1029
- FIGI
- BBG00CP3BDD4
- Share class FIGI
- BBG00CP3BDF2
- EIN
- 81-1523849
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard A. Fair | PRESIDENT AND CEO, Director | – |
| Samuel Kintz | PRESIDENT AND CEO, Director | 890,392 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | 38,000 |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | 25,000 |
| Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | 758,938 |
| Anish Patel | CHIEF OPERATING OFFICER | 235,011 |
| Lori Anne Kunkel | Director | 52,925 |
| Kristine M. Ball | Director | – |
| J. Scott Garland | Director | 0 |
| Mika K. Derynck | Director | 87,373 |
| Richard A. Heyman | Director | 146,320 |
| Jake Bauer | Director | 87,372 |
| Rahul D. Ballal | Director | 22,341 |
| Rishi Gupta | Director | 7,663,349 |
| Andrew John Phillips | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Richard Fair | $11.92M | $8.47M | $3.47M | $111 | – |
| FY2025 Sam Kintz | $8.91M | -$3.93M | $3.47M | $111 | – |
| FY2024 | $5.46M | $11.75M | $2.75M | $163 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Richard Fair President and Chief Executive Officer | $38.08K | $11.88M | – | $711 | $11.92M | – |
| Sam Kintz Former President and Chief Executive Officer | $624.15K | $7.95M | $316.80K | $15.14K | $8.91M | +63% |
| Helen Collins Chief Medical Officer | $523.00K | $2.78M | $188.28K | $15.14K | $3.50M | +26% |
| Ben Hohl Chief Financial Officer | $480.00K | $2.78M | $172.80K | $15.09K | $3.44M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 12, 2020
- Offer price
- $16.00
- Securities offered
- 4,700,000
- Gross proceeds
- $75.20M
- Exchange
- Nasdaq
- First trading day
- Mar 12, 2020
- First-day close
- $60.00+275.0%
- Lock-up ends (est.)
- Sep 8, 2020
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 60 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 1, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 1, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 23, 2023 | Name change | Name changed from IMARA Inc. to Enliven Therapeutics, Inc. |
| Nov 10, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 10, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 7, 2022 | Merger vote | Definitive merger proxy statement |
| Mar 12, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 9, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?